Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05314738 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
A Phase 1 study of Progressive Keratoconus, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT05314738 is a Phase 1 study of Progressive Keratoconus that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 150 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT05314738, a Phase 1 study of Progressive Keratoconus, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.
Conditions Studied
Interventions
- COMBINATION_PRODUCT NXL Energy 1
- COMBINATION_PRODUCT NXL Energy 2
- COMBINATION_PRODUCT NXL Energy 3
- COMBINATION_PRODUCT Sham Treatment
Study Locations (3)
Alabama
- Glaukos Investigative Site - Dothan
New Jersey
- Glaukos Investigative Site - Teaneck
Ohio
- Glaukos Investigative Site - Westerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2026-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05314738
The ClinicalTrials.gov registry entry for NCT05314738 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Progressive Keratoconus appearing as the primary indexed condition, and to 4 interventions - of which NXL Energy 1 is the first listed.
NCT05314738 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, New Jersey, Ohio.
Frequently Asked Questions
What is clinical trial NCT05314738 about?
NCT05314738 is a clinical study titled "Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus". Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.
What is the current status of trial NCT05314738?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2022-03-08. Estimated completion is 2026-02.
What conditions does trial NCT05314738 study?
This clinical trial studies the following conditions: Progressive Keratoconus.
What interventions are being tested in trial NCT05314738?
The interventions under investigation include: NXL Energy 1 (COMBINATION_PRODUCT), NXL Energy 2 (COMBINATION_PRODUCT), NXL Energy 3 (COMBINATION_PRODUCT), Sham Treatment (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05314738?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05314738 being conducted?
This trial has 3 study locations across Alabama, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Progressive Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.